Perspective Therapeutics Q1 EPS Boosted by HC Wainwright

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Equities researchers at HC Wainwright raised their Q1 2026 earnings estimates for Perspective Therapeutics in a report released on Monday, March 23rd. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.30) for the quarter, up from their previous forecast of ($0.38). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics’ Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS and FY2026 earnings at ($1.06) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. The firm had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.

A number of other analysts have also issued reports on the company. B. Riley Financial lifted their target price on Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. Piper Sandler assumed coverage on Perspective Therapeutics in a report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price target for the company. UBS Group raised their price objective on Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Royal Bank Of Canada cut their target price on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 17th. Finally, BTIG Research restated a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.63.

Perspective Therapeutics Trading Up 5.4%

Perspective Therapeutics stock opened at $4.52 on Wednesday. The company has a quick ratio of 5.17, a current ratio of 5.17 and a debt-to-equity ratio of 0.01. The firm’s fifty day moving average price is $4.48 and its 200 day moving average price is $3.46. Perspective Therapeutics has a 12-month low of $1.60 and a 12-month high of $6.16.

Hedge Funds Weigh In On Perspective Therapeutics

A number of large investors have recently bought and sold shares of CATX. Opaleye Management Inc. acquired a new position in Perspective Therapeutics during the 4th quarter valued at approximately $3,257,000. Patient Square Capital LP increased its position in Perspective Therapeutics by 224.3% in the fourth quarter. Patient Square Capital LP now owns 1,132,815 shares of the company’s stock worth $3,115,000 after buying an additional 783,492 shares during the period. Bank of America Corp DE lifted its stake in Perspective Therapeutics by 139.9% in the third quarter. Bank of America Corp DE now owns 785,823 shares of the company’s stock valued at $2,695,000 after buying an additional 458,323 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Perspective Therapeutics during the fourth quarter valued at $1,119,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Perspective Therapeutics by 118.4% during the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after acquiring an additional 405,612 shares during the period. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.